StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.09+0.26 (+9.19%)

Close on Nov 17, 2026Market cap $306.36MP/E –Yield –

X4 Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

X4 Pharmaceuticals's price to sales ratio was 35.7× on Nov 11, 2026, against 16.1× a year earlier. Over the last 3 years it ranged from 2.8× to 57.8×, with a median of 37.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202635.7×+18.0
2025Dec 31, 202517.6×−27.9
2021Apr 30, 202145.6×+10.6
2020Dec 31, 202034.9×−3.1
2019Dec 31, 201938.0×–

More X4 Pharmaceuticals figures

See a number that looks wrong?